Lucentis, a drug that is used to treat wet age-related macular degeneration, also helps diabetics’ vision, according to a late-stage study.
The study examines the effectiveness of Lucentis in treating diabetic macular edema (DME), the buildup of fluid and swelling in the retina. DME is a condition that can lead to blindness.
The study found that 44.8 percent of patients who were being treated with 0.3 mg of Lucentis showed dramatic improvement after 24 months – they were able to read at least 15 additional letters on an eye chart, according to Reuters.
These patients fared much better than the 39.2 percent of patients given 0.5 mg of Lucentis and the 18.1 percent of patients who received a placebo injection, according to the drug’s manufacturer Roche.